Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study

Shuya Kandori, Takayuki Yoshino, Masakazu Tsutsumi, Atsushi Yamauchi, Mikinobu Ohtani, Yoshiharu Fukuhara, Naoto Miyanaga, Jun Miyazaki, Hiroyuki Nishiyama, Toru Shimazui

Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Department of Urology, Hitachi General Hospital, Hitachi, Japan
Department of Urology, Ibaraki Prefectural Central Hospital, Kasama, Japan
Department of Urology, Mito Saiseikai General Hospital, Mito, Japan
Department of Urology, Ibaraki Clinical Education and Training Center, Faculty of Medicine, University of Tsukuba, Japan

Article history:
Received 28 June 2016
Received in revised form 1 September 2016
Accepted 7 September 2016
Available online 20 September 2016

Keywords:
Castration-resistant prostate cancer
Cause-specific survival
Docetaxel
Secondary hormonal therapies

Background: We retrospectively analyzed castration-resistant prostate cancer (CRPC) patients treated with secondary hormonal therapies (SHTs) prior to docetaxel therapy.

Methods: The cases of 73 CRPC patients who underwent docetaxel therapy in 2005–2011 at four hospitals in Ibaraki, Japan were analyzed. We determined the cause-specific survival (CSS) from the start of docetaxel therapy and the time point of CRPC diagnosis, and we compared the CSS achieved with/without prior classical SHTs, which were defined as low-dose steroid and estramustine phosphate.

Results: Of the 73 enrolled patients, 26 underwent docetaxel therapy (DOC group), and 47 underwent SHTs (SHTs-DOC group) as the initial treatment for CRPC. In the docetaxel therapy, the rate of prostate-specific antigen responses were higher in the DOC group compared with the SHTs-DOC group (76.9% vs. 44.7%, P = 0.0066). The median CSS from the docetaxel therapy initiation was not significantly but longer in the DOC group than in the SHTs-DOC group (23.4 months vs. 16.6 months, P = 0.0969). However, the median CSS from the time of CRPC diagnosis did not significantly differ between the DOC and SHTs-DOC groups (23.4 months vs. 24.7 months, P = 0.9233). In a univariate analysis, pain and visceral metastasis appeared to be risk factors for the CSS in the SHTs-DOC group. The patients with pain and/or visceral metastasis had significantly poorer survival than those without these factors in the SHTs-DOC group (31.5 months vs. 16.8 months, P = 0.0053).

Conclusion: The induction of SHTs prior to docetaxel therapy is an acceptable treatment option with some survival benefits for CRPC patients without pain and visceral metastases.

Copyright © 2016 Asian Pacific Prostate Society, Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Among men in Western industrialized countries, prostate cancer (PC) is the most frequently diagnosed malignant disease and the second leading cause of cancer-specific mortality. In Japan, the incidence of PC has markedly increased in recent years, and 21% of PC patients present with distant metastases; 19% present with locally advanced disease at diagnosis. With this high incidence of advanced disease, androgen-deprivation therapy (ADT) is a mainstay of treatment for locally advanced and metastatic PC. ADT is reported to be effective for <3–5 years as an average interval, but cases of castrated PC eventually transform into castration-resistant PC (CRPC).

Docetaxel, which is the current standard first-line chemotherapeutic agent for CRPC, has shown survival and palliative benefits in the TAX327 and the Southwest Oncology Group 99-16 studies. Several new agents such as abiraterone, enzalutamide, and...
cabazitaxel were shown to have a survival benefit against CRPC in Phase 3 trials.\textsuperscript{7–11} However, the optimal sequencing of treatment for CRPC has not yet been established.

The classical secondary hormonal therapies (SHTs) such as corticosteroids and estramustine phosphate (EMP) are described as options for first-line systemic therapy for CRPC without visceral metastases in the National Comprehensive Cancer Network Clinical Practice Guidelines for Prostate Cancer, version 1.2.\textsuperscript{12} However, Armstrong et al\textsuperscript{13} demonstrated that the prior use of EMP is a risk factor for the survival of CRPC patients undergoing docetaxel therapy. Although there is insufficient data supporting the classical SHTs as first-line systemic therapy for CRPC, it may be true that the majority of CRPC patients should be administered docetaxel therapy prior to SHTs before receiving any of the emerging new agents in Japan.

Therefore, in the present study we investigated whether classical SHTs could affect the response to docetaxel therapy and the survival of CRPC patients. We also analyzed the clinical factors that could be used to determine whether or not classical SHTs are feasible prior to docetaxel therapy in CRPC patients.

2. Materials and methods

2.1. Patients

Between 2005 and 2011, a total of 73 patients who received docetaxel therapy at four hospitals in Ibaraki prefecture, Japan were enrolled in this multi-institution retrospective cohort study. The eligible patients had histologically confirmed adenocarcinoma of the prostate, as clinically diagnosed CRPC. The Prostate Cancer Clinical Trials Working Group advises classifying tumors that are progressing with castration levels of testosterone as “castration-resistant”.\textsuperscript{14} We defined CRPC by disease progression after the administration of ADT, because the serum levels of testosterone of some patients were not measured. Disease progression was defined by prostate-specific antigen (PSA) progression or by radiographic imaging studies. PSA progression was defined as an increase by ≥ 25% in serum PSA (at least 2 ng/mL) from the nadir value.

We evaluated the results of the patients’ radiographic imaging studies using the Response Evaluation Criteria in Solid Tumors version 1.1. We excluded the patients who had prior treatment with cytotoxic agents other than EMP from this study. To analyze the differences in CRPC treatment types, we divided the patients into two groups. The patients who underwent docetaxel therapy as the initial treatment for CRPC were classified as the DOC group. After the initial docetaxel therapy, these patients underwent other treatment, e.g., with SHTs, other chemotherapy, and best supportive care. The patients who underwent docetaxel therapy after classical SHTs were classified as the SHTs-DOC group.

The data at the diagnosis of CRPC included the patient’s age, performance status, presence of pain, laboratory evaluations (hemoglobin, alkaline phosphate, and PSA), and site of metastases. The follow-up status data were collected in March 2016. The median duration of follow-up was 23.4 months (range, 1.53–101.2 months). The institutional review board of four hospitals approved this study, as the registry form was anonymous.

2.2. Evaluation of PSA doubling time

The PSA doubling time (PSADT) was defined as the time required for the PSA level to double. The PSADT was estimated according to the following formula:

\[
\text{PSADT} = \ln 2 \times \frac{T}{\ln(PSA_2) - \ln(PSA_1)}
\]

where \(\ln\) is the natural log, and \(T\) is the number of months between two consecutive PSA determinations (\(PSA_1\) and \(PSA_2\)).\textsuperscript{15} \(PSA_1\) is the value at the time of the diagnosis of CRPC, and \(PSA_2\) is the value at the start of the initial treatment for CRPC. The PSADTs were determined by two measurements of the PSA value at least 4 weeks apart.

2.3. Treatment

The docetaxel therapy was given in a regimen of every 3 weeks docetaxel (70–75 mg/m²) based on the schedule reported by Tannock et al,\textsuperscript{3} and 5-mg prednisone was generally administered twice daily. The adjustment of the treatment schedule and any dose reduction in docetaxel therapy were determined by the treating physician’s recommendation. The agent of classical SHTs was defined as low-dose steroid (prednisone 10 mg/d or dexamethasone 0.5–1.5 mg/d) and EMP.

2.4. Statistical analysis

The primary objective of this study was defined as the cause-specific survival (CSS) after either the induction of docetaxel therapy or the time point of the diagnosis of CRPC between the SHTs-DOC group and the DOC group. Survival curves were constructed using the Kaplan–Meier method, and the difference between the curves was evaluated using the Log Rank test. As the secondary objective, we analyzed prognosis-related risk factors in the SHTs-DOC group with univariate and multivariate analysis using Cox’s proportional hazards model and the Log Rank test. We selected the known prognostic factors for multivariate analysis with the

| Table 1 | Baseline characteristics of the 73 patients with castration-resistant prostate cancer (CRPC). |
|--------|-----------------------------------------------------------------------------------------------|
|        | DOC group (n = 26) | SHTs-DOC group (n = 47) | \(P\) |
| Age (y) | Median 68.0 | 70.0 | 0.3681 |
|         | Range 39–81 | 54–83 | |
|         | Gleason score > 7 (%) | 83.3 | 86.1 | 0.7370 |
| Prior treatment (%) | 69.2 | 89.4 | 0.0527 |
| Antiandrogen withdrawal | 84.6 | 70.2 | 0.2575 |
| ECOG performance status (%) | 0–1 | 96.2 | 89.4 | 0.4118 |
| 2 | 3.8 | 10.6 | |
| Pain (%) | 34.6 | 21.3 | 0.2685 |
| Serum PSA (ng/mL) | Median 42.0 | 26.5 | 0.5189 |
|         | Range 2.24–2379 | 2.43–924 | |
| Anemia, % (Hb < 12 g/dL) | 50.0 | 31.0 | 0.1319 |
| ALP (U/L) | Median 310 | 331 | 0.9049 |
|         | Range 164–4061 | 146–2789 | |
| Extent of disease (%) | Bone metastasis | 73.1 | 78.7 | 0.5783 |
|         | Visceral metastasis | 19.2 | 10.6 | 0.3140 |
|         | PSADT (mo) | 1.04 | 1.30 | 0.2199 |
|         | Time from starting PADT to CRPC (mo) | 0.01–7.38 | 0.02–10.7 | |
|         | Median 15.7 | 23.3 | 0.1313 |
|         | Range 3.0–134.1 | 6.1–163.5 | |
|         | Alive (%) | 15.4 | 4.3 | 0.1775 |
|         | Dead (%) | 84.6 | 95.7 | |
|         | Cancer/other causes (%) | 73.1/11.5 | 95.7/0 | |

ALP, alkaline phosphatase; DOC, docetaxel; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; PADT, primary androgen deprivation therapy; PSA, prostate-specific antigen; PSADT, PSA doubling time; SHTs, secondary hormonal therapies.
following conditions, i.e., the factors could be assessed in all patients and were not confounder with the variables detected by univariate analysis. We then investigated the differences in the CSS from the time point of the diagnosis of CRPC classified by a combination of significant factors according to the above statistics. Additionally, we analyzed the difference in PSA responses between the DOC group and the SHTs-DOC group by Fisher’s exact test. “PSA response” was defined as a >50% decline following docetaxel therapy compared with the pretreatment PSA. Differences between the two patient groups in baseline characteristics were analyzed with the Chi-square test or Wilcoxon rank sum test. A probability (P) value < 0.05 was considered significant.

3. Results

3.1. Patient characteristics

Among the 73 enrolled patients, 26 patients underwent docetaxel therapy (the DOC group), and 47 patients underwent SHTs (the SHTs-DOC group) as the initial treatment for CRPC. The characteristics of the enrolled patients are summarized in Table 1. Most of the patients in this cohort undertook an alternative antiandrogen therapy and antiandrogen withdrawal. No significant difference in patient characteristics was observed between the DOC and SHTs-DOC groups.

3.2. Analysis of PSA responses and CSS following docetaxel therapy

The PSA responses to docetaxel therapy were significantly higher in the DOC group compared with the SHTs-DOC group (76.9% vs. 44.7%, P = 0.0066; Fig. 1A). Moreover, the median CSS from starting docetaxel therapy was longer in the DOC group than that in the SHTs-DOC group, but the difference was not significant (23.4 months vs. 16.6 months, P = 0.0969; Fig. 1B).

3.3. Analysis of CSS from time of diagnosis of CRPC

The median CSS from the time of diagnosis of CRPC was not significantly different between the two groups (DOC group 23.4 months, SHTs-DOC group 24.7 months, P = 0.9233; Fig. 2). The univariate analysis to analyze the prognosis-related risk factors in the SHTs-DOC group identified visceral metastasis and pain as significant factors associated with CSS (Table 2). There were no significant prognosis-related risk factors in multivariate analysis, but the hazard ratio of visceral metastasis and pain was still higher compared with the other factors.

The following statistics with risk classification, assessed by visceral metastasis and/or pain in the SHTs-DOC group, demonstrated that the median CSS form the diagnosis of CRPC was significant shorter in the high-risk group compared with the low-risk group (16.8 months vs. 31.5 months, P = 0.0053; Fig. 3). In low-risk group, the median CSS form the time of diagnosis of CRPC was not significantly different between the DOC group and SHTs-DOC group (31.5 months vs. 31.5 months, P = 0.9139; data not shown).

4. Discussion

Docetaxel-based chemotherapy showed a survival benefit for CRPC patients in the TAX327 and the Southwest Oncology Group 99-16 studies. Although the efficacy of the new agents for CRPC has been demonstrated in recent years, docetaxel is still standard as a first-line chemotherapy agent for CRPC patients. However, there is no high-level evidence regarding which type(s) of patients with CRPC should be administered docetaxel-based chemotherapy.
Chi et al. suggested the following treatment algorithm for CRPC patients without pain and visceral metastases. CRPC is not curable, and so therapeutic strategies should be considered from a viewpoint of optimizing a patient's quality of life (QOL). We could not compare QOL between the DOC group and SHTs-DOC group in this retrospective study. However, the prechemotherapy phase is important because the adverse events of chemotherapeutic agents such as docetaxel and cabazitaxel reduce a patient's QOL. We thus speculate that SHTs including ARAT therapies are suitable for treating CRPC patients without pain and visceral metastases, particularly in Asian patients including Japanese. In classical SHTs, estrogen agents such as EMP and diethylstilbestrol are associated with cardiovascular and thromboembolic complications. Notably, ARAT therapies are more than 10 times as expensive as classical SHTs in Japan.

The limitations of this study are that it was a retrospective study with a small sample size, and the heterogeneous background of the patients. Missing laboratory data may have influenced the results. In some patients, we were not able to determine whether the inclusion criteria for the CRPC definition were fulfilled because the serum level of testosterone was not checked. The patients in this study were treated upon their clinician’s recommendation. Furthermore, we could not assess the measurements of patient’s QOL in this cohort. A prospective study would be necessary to resolve these limitations in future studies.

In conclusion, the early administration of docetaxel improved the PSA response of CRPC patients and their survival after starting docetaxel therapy, but a significant difference in survival after the diagnosis of CRPC was not observed between the patients with early and late initiation of docetaxel therapy. Moreover, there was good survival outcome in the patients without pain and visceral metastases, even among those treated by classical SHTs prior to docetaxel.

Conflicts of interest

No potential conflicts of interest relevant to this article were reported.

References

1. Matsuda T, Marugami T, Kamo K, Katanoda K, Aijiki W, Sobue T, et al. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2010;41:139–47.

Table 2

| Age > 70 y | ECOG performance status 2 | Gleason score > 7 | PSA > 100 ng/mL | PSADT < 1.3 mo | ALP > 700 U/mL | Bone metastasis | Visceral metastasis | Pain | Time from starting PADT to CRPC < 24 mo |
|-----------|--------------------------|------------------|-----------------|---------------|----------------|-----------------|-------------------|------|--------------------------|
| 47        | 47                       | 43               | 46              | 43            | 47             | 47              | 47                | 47   | 47                        |
| 1.46      | 0.98                     | 1.00             | 0.82            | 1.52          | 0.73           | 1.69            | 3.27              | 1.45 | 0.85                     |
| 0.78–2.71 | 0.34–2.28                | 0.45–2.68        | 0.37–1.64       | 0.81–2.86     | 0.39–1.40      | 0.82–3.94       | 1.09–8.05         | 0.81–2.51 | 0.46–1.55 |
| 0.2318     | 0.9623                   | 0.9876           | 0.5854          | 0.1902        | 0.3450         | 0.7022          | 0.0365*           | 0.0638 | 0.5919       |
| 0.2272     | 0.9624                   | 0.9876           | 0.5928          | 0.1857        | 0.3410         | 0.6942          | 0.0120*           | 0.0451* | 0.5914       |
| 1.42       | 0.87                     | 0.9876           | 0.8072          | 0.1857        | 0.3410         | 0.7294          | 1.94              | 1.90   | 0.89                     |
| 0.74–2.74  | 0.25–2.43                | 0.8072           | 0.8072          | 0.1857        | 0.3410         | 0.7294          | 0.49–6.64         | 0.65–5.37 | 0.47–1.7    |

HR 95% CI of HR P

0.0053* (univariate) 0.0080 (multivariate)

**Fig. 3.** Kaplan–Meier estimates of cause-specific survival (CSS) according to risk group classification in the secondary hormonal therapies-docetaxel (SHTs-DOC) group. CRPC, castration-resistant prostate cancer. *Statistically significant difference (P < 0.05).
3. Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. Current status of endocrine therapy for prostate cancer in Japan—analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 2007;37:775–81.

4. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27:4306–13.

5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.

6. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.

7. Fizazi K, Scher H, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–92.

8. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–48.

9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.

10. Beer TM, Armstrong AJ, Rathkopf DE, Liorit Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.

11. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kokac I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–54.

12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (version 1.2015) [Internet]. Available from http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

13. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010;46:517–25.

14. Scher HI, Hasabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148–59.

15. Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18:1828–33.

16. Song G, Lee C, You D, Jeong IG, Hong JH, Ahn H, et al. Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. Prostate Int 2013;1:125–32.

17. Chi K, Hotte J, Joshua AM, North S, Wyatt AW, Collins LL, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 2015;26:2044–56.

18. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, et al. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int 2011;108:1782–6.

19. Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Birker MO, et al. Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int 2012;110:E826–9.